Innovative, human-level AI technology will improve efficiency and consistency of Inflammatory Bowel Disease (IBD) scoring, advancing clinical trials of novel treatments for these debilitating ailments.
PHILADELPHIA and COPENHAGEN, Denmark and SAN MATEO, Calif. and BOSTON and JERUSALEM, March 6, 2023 /PRNewswire/ — Clario, a leading healthcare research and technology company that generates the richest clinical evidence for the clinical trials industry and GI Reviewers, LLC Gastroenterology consultants and central readers, together with RSIP Vision, an experienced developer of groundbreaking AI technologies for medical imaging, today announced their new AI-based scoring system for inflammatory bowel diseases. The solution is expected to improve the reproducibility of colonoscopy video scoring, optimize workflow by shortening the time required for a human expert reader to score, and ultimately improve recruitment and reduce costs associated with clinical trials. Peer-reviewed results demonstrating the human-level performance of this innovative system were presented to the pharmaceutical and clinical trials industry community at the prestigious European Crohn’s and Colitis (ECCO) conference this week.